The Management of Polycythaemia Vera

References

• Diez Martin, J. L., Graham, D. L., Petitt, R. M., Dewald, G. W. (1991). Chromosome studies in 104 patients with polycythemia vera. Mayo. Clin. Proc., 66, 287–299.
   PubMed Web of Science ®Google Scholar
• Swolin, B., Weinfeld, A., Westin, J. (1988). A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood, 72, 386–395.
   PubMed Web of Science ®Google Scholar
• Najean, Y., Mugnier, P, Dresch, C., Rain, J-D. (1987). Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br. J. Haematol., 67, 285–291.
   PubMed Web of Science ®Google Scholar
• Barabas, A. P., Offen, D. N., Meinhard, E. A. (1973). The arterial complications of polycythaemia vera. Br. J. Surg., 60, 183–187.
   PubMed Web of Science ®Google Scholar
• Gruppo Italiano Studio Policitemia (1995). Polycythemia Vera: the natural history of 1213 patients followed for 20 years. Annals of Int. Med., 123, 656–664.
   PubMed Web of Science ®Google Scholar
• Pearson, T. C. (1977). Clinical and laboratory studies in the polycythaemias. M.D. Thesis. (London University).
   Google Scholar
• Pearson, T. C., Wetherley-Mein, G. (1979). The course and complications of idiopathic erythrocytosis. Clin. and. Lab. Haematol., 1, 189–196.
   PubMedGoogle Scholar
• Najean, Y., Triebel, F., Dresch, C. (1981). Pure erythrocytosis: Reappraisal of a study of 51 cases. Am. J. Hematol., 10, 129–136.
   PubMed Web of Science ®Google Scholar
• van Genderen, P. J. J., Michiels, J. J. (1994). Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. La Presse Médicale, 23, 73–77.
   PubMed Web of Science ®Google Scholar
• Pearson, T. C. (1987). Rheology of the absolute polycythaemias. Bailliéres Clinical Haematology, 1, 637–664.
   PubMedGoogle Scholar
• Guthrie, D. L., Pearson, T. C. (1982). PCV measurement in the management of polycythaemic patients. Clin. Lab. Haematol., 4, 257–265.
   PubMedGoogle Scholar
• Thomas, D. J., du Boulay, G. H., Marshall, J., Pearson, T. C., Ross Russell, R. W., Symon, L., Wetherley-Mein, G., Zilkha, E. (1977). Cerebral blood flow in polycythaemia. Lancet, ii, 161–163.
   Google Scholar
• Wade, J. P. H. (1983). Transport of oxygen to the brain in patients with elevated haematocrit values before and after venesection. Brain, 106, 513–523.
   PubMed Web of Science ®Google Scholar
• Messinezy, M., Nunan, T. O., Pearson, T. C. (1993). Brain perfusion in polycythaemia using 99TcmHMPAO: effect of treatment. Eur. J. Haematol., 51, 120–121.
   PubMed Web of Science ®Google Scholar
• Willison, J. R., du Boulay, G. H., Paul, E. A., Ross Russell, R. W., Thomas, D. J., Marshall, J., Pearson, T. C., Symon, L., Wetherley-Mein, G. (1980). Effect of high haematocrit on alertness. Lancet, i, 846–848.
   Google Scholar
• Pearson, T. C., Wetherley-Mein (1978). Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet, ii, 1219–1222.
   Google Scholar
• Messinezy, M., Pearson, T. C., Prochazka, A., Wetherley-Mein, G. (1985). Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. Br. J. Haematol., 61, 657–666.
   PubMed Web of Science ®Google Scholar
• Kannel, W. B., Gordan, T., Wolf, P. A., McNamara, P. (1972). Hemoglobin and the risk of cerebral infarction: the Framingham study. Stroke, 3, 409–420.
   PubMed Web of Science ®Google Scholar
• Tohgi, H., Yamanouchi, H., Murakami, M., Kameyama, M. (1978). Importance of the hematocrit as a risk factor in cerebral infarction. Stroke, 9, 369–374.
   PubMed Web of Science ®Google Scholar
• Randi, M. L., Fabris, F., Girolami, A. (1990). Thrombocytosis in young people: Evaluation of 57 cases diagnosed before the age of 40. Blut, 60, 233–237.
   PubMedGoogle Scholar
• Frezzato, M., Ruggeri, M., Castaman, G., Rodeghiero, F. (1993). Polycythemia vera and essential thrombocythemia in young patients. Supplement di Haematologica, 78, 11–17.
   PubMedGoogle Scholar
• Van de Pette, J. E. W., Prochazka, A. V., Pearson, T. C., Singh, A. K., Dickson, E. R., Wetherley-Mein, G. (1986). Primary thrombocythaemia treated with busulphan. Br. J. Haem., 62, 229–237.
   PubMed Web of Science ®Google Scholar
• Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., Barbui, T. (1995). Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New. Eng. J. Med., 332, 1132–1136.
   PubMed Web of Science ®Google Scholar
• Landaw, S. A. (1995). Acute leukemia in polycythemia vera. In. ‘Polycythemia vera and the myeloproliferative disorders’, edited by L. R. Wasserman, P. D. Berk, N. I. Berlin, pp. 154–165. Philadelphia: Saunders Company Publishers.
   Google Scholar
• Najean, Y., Deschamps, A., Dresch, C., Damniel, M. T., Rain, J. D., Arrago, J. P. (1988). Acute leukaemia and myelodysplasia in polycythemia vera. Cancer, 61, 89–95.
   PubMed Web of Science ®Google Scholar
• Najean, Y., Dresch, C., Rain, J. D. (1994). The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br. J. Haematol., 86, 233–235.
   PubMed Web of Science ®Google Scholar
• Messinezy, M., Pearson, T. C. (1995). Incidence of myelofibrosis following treatment of primary polycythaemia by venesection. Br. J. Haematol., 89, 228–230.
   PubMed Web of Science ®Google Scholar
• Hirsch, J., Dalen, J. E., Fuster, V., Harker, L. B., Patrono, C., Roth, G. (1995). Aspirin and other platelet-active drugs. The. relationship among dose, effectiveness, and side effects. Chest, 108, Supplement, 247S–257S.
   PubMed Web of Science ®Google Scholar
• Berk, P. D., Wasserman, L. R., Fruchtman, S. M., Goldberg, J. D. (1995). Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In ‘Polycythemia vera and the myeloproliferative disorders’ edited by L. R. Wasserman, P. D. Berk, and N. I. Berlin, pp. 166–194. Philadelphia: Saunders Company Publishers.
   Google Scholar
• Nand, S., Messmore, H., Gross Fisher, S., Lourdes Bird, M., Schulzt, W., Fisher, R. I. (1990). Leukaemic transformation in polycytheamia vera: analysis of risk factors. Am. J. Hematol., 34, 32–36.
   PubMed Web of Science ®Google Scholar
• Fruchtman, S. M., Wasserman, L. R. (1995). Therapeutic recommendation for polycythemia vera. In ‘Polycythemia vera and the myeloproliferative disorders’ edited by L. R. Wasserman, P. D. Berk, N. I. Berlin, pp 337–349. Philadelphia: Saunders Company Publishers.
   Google Scholar
• Modan, B., Lilienfeld, A. M. (1964). Leukaemogenic effect of ionizing irradiation treatment in polycythaemia. Lancet, ii, 439–441.
   Google Scholar
• Najean, Y., Rain, J. D., Dresch, C., Goguel, A., Lejeune, F., Echard, E., Grange, M. J. (1996). Risk of leukemia carcinoma and myelofibrosis in P32 or chemotherapy-treated patients with polycythemia vera: a prospective analysis of 682 cases. Leukaemia and Lymphoma (in press).
   Google Scholar
• EORTC (1981). Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. Br. J. Cancer, 44, 75–80.
   PubMed Web of Science ®Google Scholar
• Brandt, L., Anderson, H. (1995). Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: Are safer drugs available? Eur. J. Haematol., 54, 21–26.
   PubMed Web of Science ®Google Scholar
• Boivin, P. (1993). Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea. Nouv. Rev. Fr. Hematol., 35, 491–498.
   PubMedGoogle Scholar
• Tartaglia, A. P., Goldberg, J. D., Berk, P. D., Wasserman, L. R. (1986). Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin, in Hematol., 23, 172–176.
   PubMed Web of Science ®Google Scholar
• Brodsky, I. (1982). Busulphan treatment of polycythaemia vera. Br. J. Haematol., 52, 1–6.
   PubMed Web of Science ®Google Scholar
• Brusamolino, E., Salvaneschie, L., Canevari, A., Bernasconi, C. (1984). Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukaemia. J. Clin. Oncol., 2, 558–561.
   PubMed Web of Science ®Google Scholar
• Weinfeld, A., Swolin, B., Westin, J. (1994). Acute leukaemia after hydroxyurea therapy in polycythemia vera and allied disorders. Eur. J. Haem., 52, 134–139.
   PubMed Web of Science ®Google Scholar
• Kaplan, M. E., Mack, K., Goldberg, J. D., Donovan, P. B., Berk, P. D., Wasserman, L. R. (1986). Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin, in Haematol., 23, 167–171.
   PubMed Web of Science ®Google Scholar
• West, O. W. (1987). Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period. Southern Medical Journal, 80, 323–327.
   PubMed Web of Science ®Google Scholar
• Holcombe, R. F., Treseler, P. A., Rosenthal, D. S. (1991). Chronic myelomonocytic leukaemia transformation in polycythemia vera. Leukemia, 5, 606–610.
   PubMed Web of Science ®Google Scholar
• Najean, Y. (1992). Traitement des polyglobulies par hydroxyurée ou pipobroman. Presse Méd., 21, 1753–1757.
   PubMed Web of Science ®Google Scholar
• Reilly, J. T., Vellenga, E., de Wolff, J. Th. M. (1996). Interferon treatment in polycythemia vera. Leukaemia and Lymphoma, 22, Suppl. 1, 143–148.
   PubMed Web of Science ®Google Scholar
• Hino, M., Futami, E., Okuno, S., Nishizawa, Y., Morii, H. (1993). Possible selective effects of interferon α-2b on a malignant clone in a case of polycythemia vera. Ann. of. Hem., 66, 161–162.
   PubMed Web of Science ®Google Scholar
• Messora, C., Bensi, L., Veochi, A., Longo, R., Giacobbi, F., Temperani, P, Bevini, M., Emilia, G., Sacchi, S. (1994). Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br. J. Haematol., 86, 402–404.
   PubMed Web of Science ®Google Scholar
• Anagrelide Study Group (1992). Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am. J. Med., 92, 69–76.
   PubMed Web of Science ®Google Scholar
• Schafer, A. I. (1984). Bleeding and thrombosis in the myeloproliferative disorders. Blood, 64, 1–12.
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration (1994). Collaborative overview of randomized trials of antiplatelet therapy—Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. B.M.J., 308, 81–105.
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration (1994). Collaborative overview of randomized trials of antiplatelet therapy—III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. B.M.J., 308, 235–245.
   PubMed Web of Science ®Google Scholar